Skip to content

International Journal of Mental Health Nursing

ISSN 1445-8330

3 papers in the library · 26 citations · publishing 2023-2025

Papers

Experiences of psilocybin treatment for clinical conditions: A qualitative meta‐synthesis

International Journal of Mental Health Nursing February 13, 2023 Marie Crowe, Jenni Manuel, Dave Carlyle et al. 18 citations

People treated with psilocybin across various health conditions—cancer, depression, HIV, substance use disorder, smoking cessation, and trauma—describe their experiences in three common themes: acceptance, connection, and transformation. A qualitative meta-synthesis of ten studies found that these themes emerged regardless of the specific health condition being treated. The review offers insights into the subjective experience of psilocybin and its effects on health, helping mental health nurses and other clinicians understand the therapeutic process from the patient's perspective.

Psilocybin‐assisted psychotherapy for treatment‐resistant depression: Which psychotherapy?

International Journal of Mental Health Nursing August 17, 2023 Marie Crowe, Jenni Manuel, Dave Carlyle et al. 6 citations

This perspective paper examines which one-to-one psychotherapies best align with the psilocybin experience for treating treatment-resistant depression. Evidence from a Cochrane review and a qualitative meta-synthesis indicates that the chosen psychotherapy must prioritize subjective experience, facilitate emotional processing, support connectedness with others, foster self-acceptance, and encourage change based on personal insights. Interpersonal psychotherapy and intensive short-term dynamic psychotherapy are found to be congruent with the psilocybin experience, though other therapies are currently being trialled.

The Acceptability of Psychedelic‐Assisted Therapy Amongst Mental Health Consumers: Utilising the Theory of Planned Behaviour

International Journal of Mental Health Nursing February 1, 2025 Eva Louie, Ellen Towers, Alyssa R Morse et al. 2 citations

Three-quarters of 254 mental health consumers surveyed in Australia expressed a desire to access psychedelic-assisted therapies (PATs) following government approval of MDMA for PTSD and psilocybin for treatment-resistant depression. Acceptability scores showed strong agreement about PAT effectiveness, moderate social endorsement, and mixed feelings about expected efficacy. While prior recreational psychedelic use was linked to higher acceptability, multivariate analysis revealed that intentions to access PAT were more strongly associated with higher acceptability scores and poorer experiences with conventional therapy. Consumers seeking alternatives to conventional treatment may view PATs as desirable despite safety reservations.